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Immune response to the carcinoembryonic antigen in patients
treated with an anti-idiotype antibody vaccine.
K A Foon, … , H Köhler, M Bhattacharya-Chatterjee
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We have generated an IgG1 murine monoclonal anti-idiotype antibody (Ab2) designated 3H1, which mimics a specific
epitope on the carcinoembryonic antigen (CEA). Patients with CEA positive tumors are immunologically "tolerant" to CEA.
We used 3H1 as a surrogate for CEA for vaccine therapy of 12 patients with advanced colorectal cancer. Each of the
patients received a minimum of four intracutaneous injections of aluminum hydroxide precipitated 3H1 at either 1, 2, or 4
mg dosage per injection. 9 of 12 patients demonstrated anti-anti-idiotypic (Ab3) response to 3H1. All nine patients
generated specific anti-CEA antibody demonstrated by reactivity with radiolabeled purified CEA; some cases were
confirmed by immunoprecipitation of purified CEA. We also demonstrated Ab3 stained both autologous and allogeneic
colonic tumors. 7 of 12 patients demonstrated idiotype specific T cell proliferative responses and four also showed T cell
proliferation to CEA. Toxicity was limited to local reaction with mild fever and chills. All 12 patients eventually progressed
after finishing 4-13 dosages. This is the first report demonstrating that a vaccine therapy is capable of breaking "immune
tolerance" to CEA in patients with CEA positive tumors. Future studies will focus on treating patients with minimal residual
disease.
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and Malaya Bhattacharya-Chatterjee
Lucille Parker Markey Cancer Center and the Departments of Medicine and Microbiology and Immunology, University of Kentucky
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Abstract
Wehave generated an IgG1 murine monoclonal anti-idio-
type antibody (Ab2) designated 3H1, which mimics a spe-
cific epitope on the carcinoembryonic antigen (CEA). Pa-
tients with CEApositive tumors are immunologically "tol-
erant" to CEA. Weused 3H1 as a surrogate for CEA for
vaccine therapy of 12 patients with advanced colorectal can-
cer. Each of the patients received a minimum of four intra-
cutaneous injections of aluminum hydroxide precipitated
3H1 at either 1, 2, or 4 mg dosage per injection. 9 of 12
patients demonstrated anti-anti-idiotypic (Ab3) response
to 3H1. All nine patients generated specific anti-CEA anti-
body demonstrated by reactivity with radiolabeled purified
CEA; some cases were confirmed by immunoprecipitation
of purified CEA. Wealso demonstrated Ab3 stained both
autologous and allogeneic colonic tumors. 7 of 12 patients
demonstrated idiotype specific T cell proliferative responses
and four also showed T cell proliferation to CEA. Toxicity
was limited to local reaction with mild fever and chills. All 12
patients eventually progressed after finishing 4-13 dosages.
This is the first report demonstrating that a vaccine therapy
is capable of breaking "immune tolerance" to CEA in pa-
tients with CEA positive tumors. Future studies will focus
on treating patients with minimal residual disease. (J. Clin.
Invest. 1995. 96:334-342.) Key words: carcinoembryonic
antigen (CEA) * anti-idiotype antibody * vaccine therapy.
colorectal cancer * tumor immunology
Introduction
Carcinoembryonic antigen (CEA)' is an 18-kD glycoprotein
tumor-associated antigen present on entodermally derived neo-
plasms of the gastrointestinal tract as well as other adenocarci-
nomas ( 1). CEA is also found in the digestive organs of the
human fetus and, thus the name, CEAwas derived. Circulating
CEA can be detected in the great majority of patients with
CEApositive tumors. Specific monoclonal antibodies have been
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1. Abbreviation used in this paper: CEA, carcinoembryonic antigen.
raised against CEA (2-4) and some have been radiolabeled
for diagnostic and clinical studies (5). As with most tumor-
associated antigens which are seen as self-antigens by the im-
mune system, cancer patients are immunologically "tolerant"
to CEA, likely related to its oncofetal origin. However, a limited
number of reports from the 1970's suggested that some patients
with CEApositive tumors may have minimal humoral and cel-
lular immunity to CEA(6-10); these results are controversial.
The network hypothesis of Lindemann and Jerne (11, 12)
offers an elegant approach to transform epitope structures into
idiotypic determinants expressed on the surface of antibodies.
According to the network concept, immunization with a given
tumor-associated antigen will generate production of antibodies
against this tumor-associated antigen, termed Abl; this Abi is
then used to generate a series of anti-idiotype antibodies against
the Abl, termed Ab2. Some of these Ab2 molecules can effec-
tively mimic the three-dimensional structure of the tumor-asso-
ciated antigen identified by the Abl. These particular anti-idio-
types called Ab2U fit into the paratopes of Abl, and express
the internal image of the tumor-associated antigen. The Ab2,/
can induce specific immune responses similar to those induced
by the original tumor-associated antigen and can, therefore, be
used as surrogate tumor-associated antigens. Immunization with
Ab2p can lead to the generation of anti-anti-idiotype antibodies
(Ab3) that recognize the corresponding original tumor-associ-
ated antigen identified by Abl. Because of this AbI-like reactiv-
ity, the Ab3 is also called Ab ' to indicate that it might differ
in its other idiotopes from Abl.
For several reasons, we consider CEAan excellent tumor-
associated antigen for active immunotherapy with anti-idiotype
antibody. First of all, CEA is typically present at high levels
on the tumor cell surface. CEA is one of the most well-charac-
terized antigens, its gene sequence is known and its three dimen-
sional structures have been identified (13). CEAis a member
of the immunoglobulin supergene family (14) located on chro-
mosome 19 which is thought to be involved in cell-cell interac-
tions. Since CEA is considered an adhesion molecule (15, 16),
it might play an important role in the metastatic process by
mediating attachment of tumor cells to normal cells. Thus, ac-
tive immunotherapy targeted to CEAmight be particularly ben-
eficial in preventing metastasis.
Highly purified CEA is available from several sources and
it can be used conveniently in serologic assays. Inasmuch as
some of the epitopes on CEA are shared by normal tissues,
immunization with intact CEA molecule might trigger poten-
tially harmful autoimmune reactions. Whereas an Ab2P gener-
ated against an anti-CEA monoclonal antibody that recognizes
a CEA-specific epitope, would be theoretically safer and more
effective. Furthermore, Ab2fl expressed in a different molecular
environment have been shown to overcome the immunosuppres-
sion in the host by stimulating "silent clones," and/or allowing
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Table L Patient Characteristics
Patient Dosage No. Metastatic Baseline Hurnoral Date off
No. Age/sex (mg) doses disease CEAlevel response Cellular study Why off
1 72/M 4 7 lung 160 + + 3/10/94 progression
2 43/F 2 4 liver 110 + + 12/9/93 progression
3 46/F 1 4 lung, liver 140 + + 12/2/93 progression
4 61/F 2 4 lung, ileum 60 - - 12/11/93 progression
5 60/M 1 7 lung, liver 3 + - 5/2/94 progression
6 68/M 4 8 lung, liver 81 + - 5/16/94 progression
7 47/M 2 4 liver 15 + + 3/17/94 progression
8 80/F 1 4 liver 42 - - 3/17/94 progression
9 51/M 4 4 liver 210 + + 4/794 progression
10 36/M 1 8 pelvis 1 - - 6/28/94 progression
11 70/M 4 13 lung 58 + + 2/20/95 progression
12 53/F 2 5 lung, liver 35 + + 6/9/94 progression
T cell help to become active, making the overall immune re-
sponse stronger which the nominal antigen (e.g., CEA) is un-
able to do (17, 18). Therefore, an appropriate anti-idiotype
antibody would be an excellent candidate to induce anti-tumor
immunity in CEApositive cancer patients.
A number of investigators have generated anti-idiotype anti-
bodies in rats, mice, baboons and humans that mimic CEA
(19-27). Wehave generated and characterized an anti-idiotype
murine monoclonal antibody to a murine monoclonal antibody
designated 8019 that identifies a specific epitope on CEA(28).
This is a highly restricted CEA epitope that is not found on
normal adult tissues and hematopoietic cells including granulo-
cytes. The IgGl anti-idiotype antibody generated to 8019 was
shown to be an internal image by generating anti-anti-idiotypic
(Ab3) responses in mice, rabbits (29), and monkeys (30)
which recognized CEA. This anti-idiotype antibody was used
to treat the patients reported in this clinical trial.
Methods
Selection of patients. All of the patients had CEA positive advanced
colorectal carcinoma and failed standard therapies (Table I). Baseline
studies included complete physical examination, chest radiography,
computer axial tomography examination of the abdomen, serum CEA
level, routine blood counts, and chemistries. All of the patients had been
off prior therapy for at least four weeks and staging was repeated at the
conclusion of therapy.
Treatment schedule. The patients were treated intracutaneously with
either 1, 2, or 4 mg of aluminum hydroxide precipitated anti-idiotype
antibody every other week for four injections. If the patients were stable
at the end of the four injections, they were then continued with injections
on a monthly basis and evaluated every 3 mo. Patients were removed
from study if they demonstrated growth of their tumor.
Generation of anti-idiotype antibody for the clinical trial. Murine
monoclonal antibody 8019 was used to immunize syngeneic BALB/c
mice for the production of anti-idiotype antibody. Immunization of
BALB/c mice, hybridoma fusion and cloning, selection of anti-idiotype
(Ab2), and production of ascites in bulk quantities in mice were done
as previously described (31, 32). The Ab2 anti-idiotype 3H1 (IgGl)
was purified from ascites by affinity chromatography on protein A-
CL Sepharose 4B column. The purity of the isolated immunoglobulin
(> 95%) was determined by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and high pressure liquid chromatography
techniques. Sterility, pyrogenicity, polynucleotides, mycoplasma, and
adventitious virus contamination and retrovirus removal validation tests
were done in accordance with the United States Food and Drug Adminis-
tration guidelines.
Preparation of final product. To augment the immunogenicity of
anti-idiotype vaccine an adjuvant is typically required. Aluminum hy-
droxide has been approved by the United States Food and Drug Adminis-
tration for use as an adjuvant in humans. For this clinical trial, anti-
idiotype 3H1 was precipitated with aluminum hydroxide. Briefly, 1 ml
of 2% Alu-Gel S (Serva Fine Biochem, Inc., Garden City, NY) was
added to 5-mg aliquots of purified monoclonal anti-idiotype antibody.
The volume was then adjusted to 10 ml with D-PBS and the mixture
incubated on a vortex for 1 h at room temperature. The mixture was
then centrifuged at 2,000 rpm at 250C for 10 min. The amount of
antibody bound in the gel layer was determined by measuring spectro-
photometrically the amount of unbound antibody in the supernatant.
The Alu-Gel precipitated antibody was stored at 40C until use. These
procedures were performed aseptically in a laminar flow hood and the
final product was sterile and clearly labeled as anti-idiotype 3H1 Alu-
Gel and aliquoted into pyrogen-free, sterile glass vials.
The final product was tested for sterility, pyrogenicity and general
safety in guinea pigs before use. An Investigational NewDrug Applica-
tion was approved through the United States Food and Drug Administra-
tion (BB-IND 5055).
Assays for humoral immunity. The development of humoral immu-
nity induced by immunization with Alu-Gel-precipitated Ab2 was as-
sessed by testing sera obtained from patients at different time points. The
sera was initially tested for total human anti-murine-antibody responses
including anti-iso/allo/and anti-anti-idiotype antibodies by sandwich
radioimmunoassay (33). Briefly, microtiter plates were coated with 3H1
and incubated with different dilutions of patients' sera. After washing,
the antigen-antibody reaction was tagged using "2I-labeled anti-Id 3H1
in a homogeneous sandwich radioimmunoassay. Since 3H1 is injected as
intact IgGl, patients are expected to mount human anti-mouse antibody
responses.
Specific Ab3 response to Ab2. Sera from immunized patients with
positive human anti-mouse antibody responses were tested for the pres-
ence of anti-anti-idiotypic antibodies. Sera were pre-incubated with nor-
mal murine immunoglobulin to block human antibodies against isotypic
and allotypic determinants and then checked for the presence of anti-
anti-idiotype (Ab3) by reaction with the immunizing anti-idiotype
(3H1) coated onto microtiter plates. Unrelated Ab2 was used as control.
After washing, the antigen-antibody reaction was tagged using '25I-
labeled anti-idiotype reagent in a homogeneous sandwich radioimmuno-
assay as above. Pretreatment, non-immune sera and sera from normal
donors were used as controls in these assays.
Inhibition of the binding between Abl and Ab2 by patients' Ab3
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antibodies by radioimmunoassay. Pre-immune and hyperimmune patient
sera samples were treated with unrelated murine immunoglobulins to
remove anti-idiotypic and allotypic reactivities. Serial dilution's of sera
were then tested for inhibition in the Abl-Ab2 binding assay. All assays
were performed in triplicate. For direct binding inhibition assay between
AbI and Ab2, purified Ab2 3H1 was used to coat plates (500 ng/well)
and the binding of radiolabeled 8019 (Abl) to Ab2 was tested for
inhibition in the presence of different patients' hyperimmune Ab3 sera
and Abl. This demonstrated whether Ab3 in patients' sera shared idi-
otopes with 8019 (Abl). Also, this inhibition assay between Abl-Ab2
binding by Ab3 sera indicated whether Ab3 is a true anti-anti-idiotype.
Detection of anti-CEA antibodies in patients immunized with Ab2
3HI. This assay was conducted to determine whether some of the Ab3
induced in patients by monoclonal murine Ab2 were of the AbI type
and will bind to CEA. Purified CEA was radioiodinated with 1125 by
the Chloramine T method. Radiolabeled CEA (1 X 106 cpm) was re-
acted with 0.5 ml of patient's serum pre-adsorbed on protein G-Sepha-
rose beads. After reactions, the beads were washed and counted in
a gamma-ray spectrophotometer. Pre-immune sera, phosphate-buffered
saline-bovine serum albumin as well as Ab3 sera obtained from a
patient treated with an unrelated murine monoclonal antibody for T cell
lymphoma were used as controls in these assays.
Purified CEA. Purified CEAwas obtained commercially from Rou-
gier Biotech, Montreal, Canada (cat. No. 70015). CEA was isolated
from human liver metastasis of colonic tumors by perchloric acid extrac-
tion and purified twice by ion-exchange chromatography followed by
gel filtration and several steps of HPLC chromatography. The CEAis
100% pure, produced a single band at 18 kD by high power liquid
chromatography and SDS-PAGEand was immunoprecipitated as a sin-
gle band by horse as well as rabbit anti-CEA antibody. The CEAprepa-
ration was resolved into two closely migrating bands at 18 and 20 kD
by Western blot analysis using murine monoclonal anti-CEA antibody.
Werechecked the material by Western blot analysis using monoclonal
antibody 8019.
Flow cytometry analysis with Abi and patient's Ab3. CEA-positive
colorectal cancer derived LS174-T cells (1 X 106 per well) and CEA-
negative B cell lymphoma, Raji cells (1 X 106 per well) were reacted
with Abl (8019) and patient's immune sera (Ab3) at 1:100 dilution at
4°C for 60 min. After washing, the cells were incubated with either
goat anti-human or goat anti-mouse F(ab' )2 IgG-FITC labeled antibody
(Tago) for 30 min at 4°C. They were then washed twice, fixed in 2%
paraformaldehyde and analyzed by flow cytometry (FACS®&Star, Becton
Dickinson).
Purification of anti-anti-idiotypic antibody (Ab3)from hyperimmu-
nized patients' sera. 50 ml of hyperimmune serum were passed over
an immunoadsorbent column consisting of immunizing anti-idiotype
immunoglobulin (3H1) coupled to Sepharose 4B. Anti-anti-idiotypic
antibodies (Ab3 ) bound to the column were eluted with 0.1 Mglycine-
hydrochloric acid buffer (pH 2.4). The eluted antibody was neutralized
with 3M Tris, dialyzed against PBS, pH 7.2, and then passed over an
immunoadsorbent column consisting of allotype matched normal mouse
immunoglobulin coupled to Sepharose 4B to remove anti-isotypic and
anti-allotypic reactivities. Antibody that passed through was concen-
trated and used as purified Ab3. The isotype of Ab3 was determined by
ELISA using human anti-isotype specific reagents (Tago).
Epitope analysis of Ab3 by radioimmunoassay inhibition assay. To
determine whether Ab3 sera compete with Abl for binding to human
colon carcinoma cells, the binding of radioiodinated 8019 to confluent
monolayers of LS174T cells was tested for inhibition in the presence
purified Ab3 and AbI preparations.
Immunoprecipitation of CEA by Abi and Ab3. Purified CEA was
labeled with "2I by The Chloramine T-method and reacted with purified
Ab3 ( 10 gg) or AbI ( 10 jg) or unrelated control Ab3 from lymphoma
patient (10 jig) or PBS-BSA control, previously adsorbed on to protein
G-Sepharose beads. After washings, The antigen-antibody coated beads
were analyzed by SDS-PAGEaccording to the method of Laemmli (34)
and radioautographed.
Immunoperoxidase staining of tumor sections with Abl and Ab3.
The reactivities of monoclonal Abl and purified Ab3 at 10 Jig/ml solu-
tion were compared on surgical specimens of colonic adenocarcinomas
by a very sensitive staining method (biotin-Streptavidin reagents; Vec-
tor, Burlingame, CA) as described in detail elsewhere (27). All sections
were counterstained with Meyer's hematoxylin. Pertinent specificity
tests were performed, including block of the endogenous peroxidase,
omission of the first layer, or substitution of nonimmune homologous
serum for the specific antiserum and P3-653 myeloma culture superna-
tant as the control.
Assay for T cell proliferative response. Peripheral blood mononu-
clear cells were isolated by standard Ficoll-Hypaque density gradient
centrifugation method and S x 105 cells per well were incubated with
different concentrations of 3HI-Alu-Gel and control 4DC6-Alu-Gel ( 10
ng to 2 jig) in RPMI medium with 5%heat-inactivated fetal calf serum
and penicillin and streptomycin. The nonspecific mitogen phytohemag-
glutinin-P was used as a positive control at 2 and 1 jg per well. After
the cells were incubated for 5 d at 37TC in an atmosphere containing
5% carbon dioxide, they were pulsed with [3H]thymidine (1 JiLCi per
well) for 20 h. Data were expressed as mean counts (triplicate wells)
per minute of [3H]thymidine incorporation. The Standard Deviation of
the data was < 10% for each determination.
Peripheral blood mononuclear cells isolated from some selected pa-
tients were also incubated with different concentrations of purified CEA
(10-250 ng) as per protocol above.
Assay for circulating CEA in serum. CEA was quantified in heat-
extracted serum. For this, lml of 0.2 msodium acetate buffer, pH 5.0,
was added to 0.5 ml of serum, vortex-mixed, incubated for 15 min at
90TC, and centrifuged ( 1,200 g, 10 min). The supernatants were assayed
the same day or stored frozen at -20°C until assay. 100 ml of super-
natant was then assayed by the enzyme immunoassay for CEA as de-
scribed (35).
Results
Humoral responses to anti-idiotype. The development of hu-
moral immunity induced by immunization with Alu-Gel-precip-
itated Ab2, 3H1 was assessed by testing sera obtained from
patients before therapy and after each treatment with the vac-
cine. Hyperimmune sera (after the fourth injection of 3H1)
from nine of twelve patients showed significant levels of total
human anti-mouse antibody responses including anti-iso/allo/
and anti-anti-idiotypic antibodies against immunizing Ab2,
3H1, as determined by homogeneous sandwich radioimmunoas-
say (data not shown). Next the sera from these immunized
patients were checked for their ability to inhibit the binding of
'25I-labeled Abl, 8019 to Ab2 3H1 on the plate by radioimmu-
noassay or vice versa (inhibition of radiolabeled Ab2 binding
to AbI on the plate). These reactions were done in the presence
of excess normal murine immunoglobulin to block human anti-
bodies against isotypic and allotypic determinants. Fig. 1 dem-
onstrates representative data from the first five patients. Sera
from patients 1, 2, 3, and 5, at 1 / 10 dilution, inhibited binding
of iodinated 8019 to 3H1 by 62- 100% and inhibition of
binding decreased with increasing dilution of the sera. Sera
from patient 4 showed minimal nonspecific inhibition at all
dilutions used and pre-immune sera showed no inhibition. Al-
though steric hindrance by Ab3 binding can not be excluded in
these assays, the results suggest the presence of true anti-anti-
idiotypic antibodies that share idiotypes with Abl. Again, nine
out of twelve patients were positive for Ab3 responses by this
assay.
Induction of anti-CEA antibodies by anti-idiotype 3H1.
Next, we investigated whether 3H1 could induce an anti-CEA
antibody response in immunized patients. For this, the crude
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Figure 1. Inhibition of Abl (8019) binding to Ab2 (3H1) on the plate
by patients' Ab3 sera by radioimmunoassay. Purified 3H1 was used to
coat the plate (500 ng/well) and the binding of radiolabeled 8019
(- 90,000 cpm) to 3H1 was tested for inhibition in the presence of
various dilutions of Ab3 sera obtained from patients after the fourth
immunization.
sera obtained from patients after the fourth treatment were tested
for the presence of antibody binding to radiolabeled purified
CEA. Weroutinely used post fourth immunization because this
was the number of injections all 12 patients received. For pa-
tients who received more than four injections, immune re-
sponses remained comparable or continued to increase in titer.
A pure preparation of CEA was used to reduce the risk of
obtaining false positive results due to nonspecific binding. As
shown in Fig. 2, immunization with 3H1 induced antibodies
that bound to radiolabeled CEA. Nine of twelve patients devel-
oped anti-CEA antibodies measurable by this assay. Patients 4,
8, and 10 were anergic for human anti-mouse antibody re-
sponse and did not produce antibodies against CEA, while pa-
tients 1, 2, 3, 5, and 12 showed high binding, and patients 6,
7, 9, and 11 showed binding greater than the background count
obtained with PBS-BSA (Sample 13) or pre-immune sera (data
not shown). Sample 14 was the AbI 8019 antibody used as a
positive anti-CEA (8019) control.
Immuneflow cytometry analysis with Abl and patient's Ab3.
To determine the reactivity with cell-surface CEA, cultured
CEApositive human colon cancer LS174T cells were tested by
immune flow cytometry. As shown in Fig. 3, crude sera from
a representative 3Hl-immunized patient bound to LS174 T cells
(A) similar to the binding pattern obtained with 8019 (B) and
did not bind to human B cell lymphoma cells which do not
express CEA(Fig. 3 C). Similar results were found with all of
the positive patients.
Competition of Abl and patient's Ab3for binding to LS] 74-
T cells. If Ab3 has a similar binding site as Abi, it should
compete with AbI for binding to CEA on LS174-T cells. A
fixed amount of radiolabeled 8019 was co-incubated with differ-
ent concentrations of patientUs purified Ab3 or AbI prepara-
tions and LS174-T cells (Fig. 4).
Purified 8019-IgGI (Abi ) inhibited binding by 80% at 0.75
.g whereas patient's purified Ab3 (from patient 1) produced
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Figure 2. Reactivity of patients' Ab3 with purified radiolabeled CEA.
Patients' sera (0.5 ml) obtained after the fourth immunization was ad-
sorbed on to protein G-Sepharose 4B beads and reacted with (- I
x 106 cpm) radiolabeled CEA. After the reaction, the mixture was
centrifuged, the precipitate was washed and counted in a gamma-
counter. Each sample was performed in duplicate and the mean of the
cpm bound is shown. Samples 1 through 12 were obtained from patients
1 through 12. Sample 13 was PBS-BSA control and 15 was AbI 8019,
used at 10 jig concentration. No reactivity (cpm bound) greater than
PBS-BSA was observed with pre-immune sera from these patients.
curves obtained with AbI and Ab3 were very similar at different
dilutions. This indicated that the patient's Ab3 bound to the
same antigenic epitope as Abi and therefore contained antibody
molecules with Abl' properties.
Immunoprecipitation of CEA by AbN and Ab3. It had been
previously shown that AbM 8019 specifically immunoprecipi-
tated the 18 kD CEAby SDS-PAGEanalysis (29). To confirm
that the Ab3 induced by 3H1 was specific for the CEAmolecule,
the iodinated purified CEApreparation was immunoprecipitated
by purified Ab3 preparations obtained from two patients as well
as Abl and analyzed by SDS-PAGE. The results in Fig. 5
indicate that both patient's Ab3 (lanes 2 and 3) precipitated the
same 18 kD CEAband as that of murine Abl 8019 (lane 1).
There was no cross-reactivity (lane 4) when the iodinated CEA
was reacted with purified Ab3 obtained from a patient treated
with an unrelated Ab2 (4DC6).. When iodinated CEA, pre-
treated with either of the two positive patients' Ab3 prepara-
tions, was reacted with 8019, there was no significant immuno-
precipitation suggesting that the iodinated preparation was de-
pleted of CEA(data not shown).
Immunoreactivity of Abi and patients' Ab3 on colonic tu-
mor sections and nonnal tissues. Wecompared the reactivities
of Abl (8019) with that of patients' purified Ab3 by a sensitive
immunoperoxidase assay on autologous and allogeneic colon
tumor specimens surgically removed from patients. The pattern
of reactivity of patient Ab3 on autologous malignant colon tis-
sues was identical to that obtained with allogeneic tumor speci-
mens (Fig. 6, A and B, respectively). AbI 8019 showed identi-
cal staining patterns (Fig. 6 C), whereas there was no reactivity
with control Ab3 obtained from a patient treated with an unre-
lated Ab2 (4DC6) (Fig. 6 D). Reactions with Abl or purified
Ab3 (Fig. 6, A-C) resulted in the staining of both tumor cells
as well as secreted mucinous materials. The staining was apical
in gland-like structures and granular (cytoplasmic) in less dif-
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Figure 4. Inhibition of AbI binding to LS174-T cells by patient's Ab3.
Confluent monolayers of LS 174-T cells in microtiter plates were reacted
with different concentrations of Ab3 and AbN and a fixed amount of
'25I-8019 (- 90,000 cpm). Percent inhibition was calculated as de-












Figure 3. Flow microfluorimetry analysis of the CEApositive colon
cancer cell line, LS174-T, with patients' Ab3 sera. Tumor cells were
reacted with Ab3 sera (1/100 dilution) from patients immunized with
Ab2, 3H1 (A) and murine Abl 8019 (B). The reaction was developed
with goat anti-human or anti-mouse F(ab' )2 IgG-FITC labeled antibody
respectively. Preimmune patient's sera were used as control. In C, hu-
man B cell lymphoma cells, Raji, that do not express CEAwere reacted
with patient's Ab3 and preimmune sera. Symbols used: (-----) preim-
mune serum in A-C; ( ) Ab3 serum in A and C; and (-) AbI
8019 in B.
ferentiated areas. There was no reactivity of Abl and purified
Ab3 on normal tissues from colon (Fig. 6, E and F), cecum,
duodenum, stomach striated muscle or smooth muscle.
Cellular immune responses to anti-idiotype. Cellular im-
mune responses were measured by the proliferation of periph-
eral blood mononuclear cells incubated with Alu-Gel precipi-
tated anti-idiotype antibody 3H1 and Alu-Gel precipitated iso-
type matched control anti-idiotype antibody 4DC6. Positive
proliferative responses were seen in seven of twelve patients.
104 All seven of these patients developed an Ab3 antibody response10~ (Table I). Representative data from two patients (1 and 12) are
shown in Fig. 7, A and B. Pre-immune cells had no proliferative
response to the anti-idiotype antibody while hyperimmune cells
had a significant response. Four of the seven responding patients
(two treated with a 2-mg dose and two with a 4-mg dose) also
showed T cell proliferation in the presence of purified CEA
suggesting antigen specific T cell response. There was also a
response to the isotype matched 4DC6 Alu-Gel-precipitated
anti-idiotype antibody; this response was significantly less than
that of the 3H1 response, likely representing a response to the
non-idiotype components of the murine immunoglobulin mole-
cule. The difference in the response to 3H1-Alu-Gel compared
with control 4DC6-Alu-Gel was significant (P < 0.003) as was
the response to CEAcompared to BSA(P < 0.005). There was
no response to Alu-Gel itself (data not shown). Flow cytometric
analysis of the cultures demonstrated that > 90%of the prolifer-
ating cells were CD4positive T lymphocytes. The three patients
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Figure 6. Immunoperoxidase staining of autologous and allogeneic colonic adenocarcinomas and normal colon by Abl and patients' Ab3. Serial
sections were stained with; (A) patients' Ab3 (50 .g/ml) on autologous tumor; (B) patients' Ab3 (50 jig/ml) on allogeneic tumor; (C) 8019 IgG,
(50 ig/ml); (D) Ab3 (50 jig/ml) from patient treated with an unrelated anti-idiotype antibody (4DC6) on tumor sections as in A; (E) 8019 IgGI
(50 ,g/ml) on normal colon; (F) patients' Ab3 (50 jg/ml) on normal colon.
who were anergic for human anti-mouse antibody response also
did not demonstrate any T cell proliferative response. Of the
five nonresponders, three were treated with 1 mg, one with 2
mg and one with 4 mg dosage of 3H1-Alu-Gel.
Toxicity and clinical response. Toxicity was minimal with
only local reactions at the injection site with mild erythema and
induration and mild fever and chills relieved by acetaminophen.
The anti-idiotypic treatment did not have any deleterious effect
on hematopoietic cells, renal, or hepatic function.
All 12 patients eventually developed progressive disease (Table
I).
Serial monitoring of circulating CEA. Indirect measurement
of extent of disease (CEA level) was recorded prior to immuni-
zation and determined after each immunization and then once
monthly following completion of the immunization schedule.
For this, patients' sera was heat-inactivated to precipitate the
immunoglobulins which would interfere with the CEAmonitor-
ing assays involving murine monoclonal Abl. CEAis heat sta-
Patients were monitored very closely for disease activity. ble, and was measured in the clear centrifuged supernatant by
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,000
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Figure 7. T cell proliferation assay with patients' (No. 1, A and No.
12, B) peripheral blood mononuclear cells in the presence of 3HI-Alu-
Gel, iso-allotype matched control 4DC6-Alu-Gel, purified CEA, purified
bovine serum albumin (BSA), and phytohemagglutinin. Peripheral
blood mononuclear cells were isolated from blood obtained after four
immunizations and cultured with 100 ng of different antigens and 2 jig
of phytohemagglutinin as described in Methods. [3H]Thymidine incor-
poration was measured in pre- (solid bars) and post-therapy (hatched
bars) samples. Data are expressed as mean cpm of triplicate wells. The
S.D. of the data was < 10% for each determination.
routine assay. The serial monitoring of CEA correlated with
disease progression and all patients who clinically progressed
had a rise in their serum CEA levels except patients 5 and 10
who did not secrete CEA.
Discussion
Wehave demonstrated that nine of twelve patients injected with
aluminum hydroxide precipitated anti-idiotype antibody 3H1
generated anti-CEA antibody by direct binding to radiolabeled
purified CEA. None of these patients had pre-existing antibody
to CEA. Wealso demonstrated binding to autologous and allo-
geneic tumor as well as immunoprecipitation of purified CEAin
selected patients. While the three patients who did not generate a
humoral immune response may have been truly anergic, it is
possible that the two who had elevated CEA levels (patients 4
and 8) generated small quantities of antibody that was bound
to circulating CEA as immune complexes. Indeed, many pa-
tients had increasing levels of circulating immune complexes
as determined by routine Raji cell assay (data not shown). Also,
there is the possibility that some of the circulating anti-CEA
antibodies may have bound to patients' tumor cells or were of
low affinity. However, five of the patients still showed high
binding of antibody to radiolabeled CEA, while four others
showed modest binding. In future studies, we will also stimulate
patients' peripheral blood mononuclear cells in vitro with CEA
or Ab2 for the induction of tumor-specific antibody (36).
Seven patients demonstrated idiotype specific T cell prolif-
erative responses of primarily CD4 T cells. Four of them also
demonstrated CEA-specific T cell proliferation in vitro. Wewill
also study these patients' sera for in vitro killing of cultured
tumor cells by antibody-dependent cell-mediated cytotoxicity
(ADCC) and complement mediated cytotoxicity (CMC)
assays. Wedo not have fresh or frozen autologous tumor tissues
from these patients to test for in vitro cytotoxic T cell (CTL)
induction, but will use HLA-Class 1 matched cultured colon
tumor cell lines as targets.
To our knowledge, this is the first report in the literature
describing the generation of specific and reproducible immunity
to CEA. Whether this Ab3 and/or cellular immunity can medi-
ate a potential anti-tumor effect remains to be determined. All of
the patients in this study had prior chemotherapy and advanced
disease; tumor regression was not noted. Future studies will
focus on adjuvant trials where the goal will be elimination of
minimal residual disease.
Another approach to generate active immunity to CEAhas
been the development of a recombinant vaccinia virus express-
ing the human CEAgene (37, 38). This was made possible by
the cloning of the CEA gene (39). These investigators have
demonstrated anti-CEA immune responses in animals but have
not yet reported success in clinical trials. Another novel ap-
proach to generate CEA immunity that has not yet entered the
clinic, is cDNA immunization by a polynucleotide vaccine
(40). Other investigators have generated anti-idiotype antibod-
ies that are the internal images of CEA(19-27); clinical results
are not reported.
It was interesting that our 3H1 anti-idiotype antibody was
effective in eliciting immune responses despite the absence of
a strong adjuvant. Aluminum hydroxide-precipitation, although
considered weakly immunogenic, appeared to be quite adequate
in eliciting immune responses. Aggregation of soluble idiotypic
determinants by aluminum hydroxide precipitation likely helped
to increase its antigenicity. Also, our antibody was a foreign
protein and was injected as an intact immunoglobulin. The Fc
portion of the murine immunoglobulin probably served as a
"carrier" to help promote the immune responses. It was of
further interest that our anti-idiotype antibody and purified CEA
were able to stimulate an in vitro CD4 T cell proliferative
response in treated patients. Webelieve the response observed
in some patients against the purified CEAis based on the recog-
nition of processed idiotypic peptides which have homology to
the CEAsequence. In preliminary experiments, we have identi-
fied a peptide sequence region of CEAwhich has homology to
a CDRof the light chain of our 3H1 anti-idiotype vaccine.
A variety of non-CEA anti-idiotype antibodies have been
shown to generate active tumor immunity in animal models
with both humoral immune responses and delayed hypersensi-
tivity (41-49). Perhaps the first suggestion in man that anti-
idiotype responses might correlate with clinical responses were
in patients treated with a non-CEA AbI antibody for colorectal
cancer who developed anti-idiotypic antibodies and improved
clinically (50). Subsequent clinical trials using polyclonal non-
CEA goat anti-idiotype (Ab2) vaccines for colorectal cancer
(51), and monoclonal anti-idiotypes for malignant melanoma
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(52, 53) have demonstrated that anti-idiotype vaccine therapy
leads to active immune responses. In a recent study, idiotype-
specific immune responses were induced in patients with B cell
lymphoma against the immunoglobulin idiotype expressed by
their tumors (54). This latter study differed from ours in that
the idiotype immunogen was derived from the patients' tumors,
coupled to keyhole limpet hemocyanin and mixed with a potent
adjuvant. Therefore, while we used a single anti-idiotype anti-
body as an antigen surrogate to treat all of our patients, these
investigators generated an individualized vaccine for each of
their patients.
In summary, we have demonstrated specific active immunity
to CEAin patients with advanced colorectal cancer treated with
an anti-idiotype antibody that "mimics" CEA. In this Phase
lb clinical trial, we could only accrue patients who failed con-
ventional therapy. All of them had widespread advanced dis-
ease. The main purpose of this clinical trial was not to assess
tumor response, but to determine the host's immunological re-
sponse to the vaccine therapy. Some primary questions have
been resolved. This anti-idiotype antibody can evoke an Ab3
as well as cellular immune response in patients, and any Ab3
so derived, behaves as an Abi-like antibody (AbI ' ). The inten-
sity of the Ab3 response appeared to correlate positively with
anti-CEA antibody (Abl') and T cell proliferative responses.
Immune responses appeared independent of the level of circulat-
ing CEA. While there are too few patients to compare the 1
mg, 2 and 4 mg doses; it is clear that patients were able to
generate immunity at each of these doses. At the completion of
this study we will statistically compare the different dose levels.
Toxicity was restricted to local cutaneous reactions lasting 24-
48 h with mild fever and chills and was relieved by acetamino-
phen.
Collectively, the immune responses in patients treated with
an idiotype vaccine, which induced humoral and cellular re-
sponses against an otherwise non-immunogenic tumor antigen,
justify follow-up clinical studies in patients with minimal tumor
burden, as well as basic immunobiological studies to understand
the mechanisms of the T cell response at the clonal level. Such
studies may lead to the development of second generation idio-
type vaccines consisting of cytokine-antibody fusion proteins
(55) and of idiotype derived peptide vaccines (56).
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